Evercore ISI Group Reinstates In-Line on Quest Diagnostics, Announces $165 Price Target
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has reinstated an In-Line rating for Quest Diagnostics with a price target of $165.
August 28, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Evercore ISI Group has reinstated an In-Line rating for Quest Diagnostics with a price target of $165, indicating a neutral stance on the stock.
The reinstatement of an In-Line rating by Evercore ISI Group suggests a neutral outlook for Quest Diagnostics. The $165 price target provides a specific valuation expectation, but the In-Line rating indicates no strong buy or sell recommendation. This is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100